1 |
NCT02632318 |
Recruiting |
Dawn Simulation and Postural Hypotension |
|
|
Interventional |
Phase 4 |
- VA Palo Alto Health Care System
- Velux Fonden
- Palo Alto Veterans Institute for Research
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Sympathovagal balance derived from blood pressure measurement
|
36 |
All |
55 Years to 85 Years (Adult, Senior) |
NCT02632318 |
IRB-36269 |
|
September 2016 |
February 2019 |
February 2019 |
December 16, 2015 |
January 5, 2018 |
|
- VA Palo Alto Health Care System
Palo Alto, California, United States
|
2 |
NCT02919917 |
Recruiting |
Treatment of Post-SCI Hypotension |
- Spinal Cord Injury
- Autonomic Dysreflexia
- Orthostatic Hypotension
- (and 7 more...)
|
- Drug: Midodrine Hydrochloride
|
Interventional |
Phase 2 Phase 3 |
- James J. Peters Veterans Affairs Medical Center
- Icahn School of Medicine at Mount Sinai
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Treatment
|
- Rehabilitation
- Systolic Blood Pressure
- Orthostatic Hypotension and Autonomic Dysreflexia
- Cerebral Blood Flow
|
60 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT02919917 |
WEC-16-050 |
|
June 1, 2017 |
September 2021 |
September 2021 |
September 30, 2016 |
February 19, 2018 |
|
- VA Medical Center, Bronx
Bronx, New York, United States - Mount Sinai School of Medicine
New York, New York, United States
|
3 |
NCT02016599 |
Recruiting |
Effects of Transitional Circulation in ELBW Infants |
- Neonatal Prematurity
- Hypotension
|
- Other: Monitoring and biospecimen collection
|
Observational |
|
- Baylor College of Medicine
- Texas Children's Hospital
- National Institutes of Health (NIH)
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Quantify physiologic changes during transitional circulation
- Quantify cardiac output
- Quantify the differences in perfusion of end organs
- (and 2 more...)
|
200 |
All |
up to 1 Week (Child) |
NCT02016599 |
H-33536 1K23HL130522-01 |
|
September 22, 2017 |
August 2021 |
September 2022 |
December 20, 2013 |
January 26, 2018 |
|
- Texas Children's Hospital
Houston, Texas, United States
|
4 |
NCT02893553 |
Recruiting |
The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury |
- Spinal Cord Injury
- Autonomic Dysreflexia
- Baroreceptor Integrity
- (and 7 more...)
|
- Drug: Midodrine Hydrochloride
- Drug: Pyridostigmine Bromide
- Drug: Mirabegron
- Other: Placebo
|
Interventional |
Phase 2 |
- James J. Peters Veterans Affairs Medical Center
- Kessler Foundation
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Systolic Blood Pressure
- Cerebral Blood Flow
|
50 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02893553 |
WEC-16-015 |
|
December 2016 |
December 2019 |
December 2019 |
September 8, 2016 |
January 23, 2018 |
|
- Kessler Foundation Research Center
West Orange, New Jersey, United States - James J Peters VAMC
Bronx, New York, United States
|
5 |
NCT03301740 |
Recruiting |
Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis |
|
- Other: UF profiling during HD
- Other: Conventional HD
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage of HD treatments with intradialytic hypotension
- Magnitude of mean Troponin T change
- Magnitude of transthoracic echocardiography global longitudinal strain (GLS) change
- (and 3 more...)
|
36 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03301740 |
17-1057 1K23DK109401 |
|
March 12, 2018 |
March 2019 |
March 2020 |
October 4, 2017 |
March 21, 2018 |
|
- Carolina Dialysis - Siler City
Siler City, North Carolina, United States
|
6 |
NCT02307565 |
Recruiting |
Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury |
|
- Drug: Midodrine
- Drug: Placebo
|
Interventional |
Phase 3 |
- James J. Peters Veterans Affairs Medical Center
- Kessler Foundation
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Systolic Blood Pressure
- Cerebral Blood Flow
- Memory
- Number of Hypertensive Events
|
60 |
All |
18 Years to 65 Years (Adult) |
NCT02307565 |
WEC-13-066 |
|
March 2014 |
March 2018 |
March 2018 |
December 4, 2014 |
March 7, 2017 |
|
- Kessler Foundation Research Center
West Orange, New Jersey, United States - James J Peters VAMC
Bronx, New York, United States
|
7 |
NCT00890162 |
Recruiting |
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis |
- Anaphylaxis
- Hypotension
- Bronchospasm
- Angioedema
|
- Drug: Epinephrine
- Procedure: Bone Marrow Apsiration
- Drug: Omalizumab (Xolair)
|
Interventional |
Phase 2 |
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- The primary objective of this study is to determine if treatment with omalizumab over 6 months will produce a reduction in the number and timing of anaphylactic events in subjects with a history of frequent idiopathic anaphylaxis.
- Assess the pharmacodynamics of omalizumab in subjects with anaphylaxis. Examine the effects of omalizumab in the immunopathogenesis of anaphylaxis. Identify subjects with the D816V mutation.
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00890162 |
090129 09-I-0129 |
|
April 27, 2009 |
May 31, 2018 |
May 31, 2019 |
April 29, 2009 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
8 |
NCT02526186 |
Recruiting |
Battlefield Auricular Acupuncture for Control of Post-partum Pain |
|
- Device: Battlefield Auricular Acupuncture
|
Interventional |
Not Applicable |
- Mike O'Callaghan Military Hospital
|
U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Scores range from 0 (no pain) to 10 (worst pain)
- Decrease in amount of Pain medicine used
|
90 |
Female |
18 Years and older (Adult, Senior) |
NCT02526186 |
FWH20150072H |
|
February 2016 |
June 2018 |
June 2018 |
August 18, 2015 |
February 8, 2018 |
|
- Mike O'Callaghan Federal Medical Center
Nellis Air Force Base, Nevada, United States
|
9 |
NCT03049449 |
Recruiting |
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas |
- Lymphoma, Large-Cell, Anaplasitc
- Hodgkin Disease
- Lymphoma, Hodgkins
- (and 2 more...)
|
- Biological: Anti-CD30-CAR T cells
- Drug: Cyclophosphamide
- Drug: Fludarabine
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the safety and feasibility of administering T cells expressing a novel fully-human anti-CD30 CAR to patients with advanced CD30-expresssing lymphomas.
- Assess the immunogenicity of the CAR used in this protocol
- Evaluate the in vivo persistence and peak blood levels of anti-CD30 CAR T cells after initial and repeated CAR T-cell infusions
- Assess for evidence of antilymphoma activity by anti-CD30 CAR T cells
|
76 |
All |
18 Years to 73 Years (Adult, Senior) |
NCT03049449 |
170048 17-C-0048 |
|
March 17, 2017 |
June 30, 2021 |
June 30, 2022 |
February 10, 2017 |
April 25, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
10 |
NCT03314233 |
Recruiting |
Delayed Cord Clamping for Congenital Diaphragmatic Hernia |
- Congenital Diaphragmatic Hernia
|
|
Interventional |
Not Applicable |
- Children's Hospital of Philadelphia
- National Institutes of Health (NIH)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Proportion of infants who are intubated prior to umbilical cord clamping
- Mean Arterial potential of hydrogen (pH) in arterial blood
- Mean partial pressure of O2 in arterial blood (PaO2)
- (and 4 more...)
|
20 |
All |
up to 1 Day (Child) |
NCT03314233 |
17-014125 |
DING |
October 12, 2017 |
October 2018 |
October 2019 |
October 19, 2017 |
January 23, 2018 |
|
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
11 |
NCT02951130 |
Recruiting |
Milrinone in Congenital Diaphragmatic Hernia |
- Congenital Diaphragmatic Hernia
- Persistent Pulmonary Hypertension of the Newborn
- Hypoxemic Respiratory Failure
- Pulmonary Hypoplasia
|
- Drug: Milrinone
- Drug: Placebo (5% Dextrose)
|
Interventional |
Phase 2 |
- NICHD Neonatal Research Network
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Oxygenation Response
- Oxygenation Response at 48 and 72 h
- Changes in estimated systolic pulmonary arterial pressure on echocardiogram
- (and 11 more...)
|
66 |
All |
up to 168 Hours (Child) |
NCT02951130 |
NICHD-NRN-0057 UG1HD034216 UG1HD027904 UG1HD021364 UG1HD027853 UG1HD040689 UG1HD040492 UG1HD027851 UG1HD087229 UG1HD053109 UG1HD068278 UG1HD068244 UG1HD068263 UG1HD027880 UG1HD053089 UG1HD087226 U10HD036790 |
|
August 22, 2017 |
February 2020 |
February 2021 |
November 1, 2016 |
September 26, 2017 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Stanford University
Palo Alto, California, United States - Emory University
Atlanta, Georgia, United States - (and 13 more...)
|
12 |
NCT03256890 |
Recruiting |
Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT |
- Hypertension
- Prehypertension
|
- Behavioral: MB-BP Intervention
- Other: Enhanced Usual Care Control
|
Interventional |
Not Applicable |
- Brown University
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Systolic blood pressure
- Sustained Attention to Response Task (SART)
- Mindful Attention Awareness Scale (MAAS)
- (and 12 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03256890 |
1412001171 1UH2AT009145 |
MB-BP |
June 13, 2017 |
June 30, 2020 |
June 30, 2020 |
August 22, 2017 |
October 31, 2017 |
|
- Brown University School of Public Health
Providence, Rhode Island, United States
|
13 |
NCT03037879 |
Recruiting |
Treating Cognitive Deficits in Spinal Cord Injury |
- Spinal Cord Injury
- Blood Pressure
- Cerebral Blood Flow
- Cognitive Function
|
- Other: SPT
- Other: SPT Control
- Other: mSMT
- Other: mSMT Control
|
Interventional |
Not Applicable |
- James J. Peters Veterans Affairs Medical Center
- Kessler Foundation
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Neuropsychological Tests [Change from baseline at immediate follow up (post treatment) and long term follow-up (6months post treatment)]
- Systolic Blood Pressure [Change from baseline at immediate follow up (post treatment) and long term follow-up (6months post treatment)]
- Diastolic Blood Pressure [Change from baseline at immediate follow up (post treatment) and long term follow-up (6months post treatment)]
- Cerebral Blood Flow Velocity [Change from baseline at immediate follow up (post treatment) and long term follow-up (6months post treatment)]
|
104 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03037879 |
WEC-16-059 |
|
April 13, 2017 |
January 31, 2020 |
January 31, 2020 |
January 31, 2017 |
April 19, 2017 |
|
- Kessler Foundation
West Orange, New Jersey, United States
|
14 |
NCT03014414 |
Recruiting |
Stanford Healthy Heart Study |
|
- Behavioral: Fun First
- Behavioral: Weight Watchers
|
Interventional |
Not Applicable |
- Stanford University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportion of participants who lose a clinically significant amount of initial body weight AND maintain it during the trial (i.e., Lose >=7% of their initial body weight from 0-12 months AND gain <=5 lbs from 12-36 months), assessed by clinic scales
- Proportion of participants who lose a clinically significant amount of initial body weight AND maintain it during the trial (Lose >=7% of their initial body weight from 0-12 months AND gain <=5 lbs from 12-36 months), assessed by cellular scales
- Change in systolic blood pressure from 0-36 months
|
346 |
All |
21 Years and older (Adult, Senior) |
NCT03014414 |
37586 R01HL128666 |
|
March 4, 2017 |
June 2020 |
July 2020 |
January 9, 2017 |
April 18, 2018 |
|
- Stanford University School of Medicine
Palo Alto, California, United States
|
15 |
NCT00936325 |
Recruiting |
Studies in the Pathogenesis of Systemic Capillary Leak Syndrome |
- Systemic Capillary Leak Syndrome
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
210 |
All |
16 Years to 80 Years (Child, Adult, Senior) |
NCT00936325 |
090184 09-I-0184 |
|
July 8, 2009 |
|
|
July 10, 2009 |
April 20, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
16 |
NCT00719719 |
Recruiting |
Cause of Unexplained Anaphylaxis |
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Clinical samples obtained from the bone marrow biopsy and whole blood will be used to determine genetic and signaling abnormalities in mast cells and will be correlated with clinical features of idiopathic anaphylaxis.
- Clinical samples obtained from the bone marrow biopsy and whole blood will be used investigate the presence or absence of a monoclonal mast cell disorder.
|
200 |
All |
13 Years to 70 Years (Child, Adult, Senior) |
NCT00719719 |
080184 08-I-0184 |
|
July 18, 2008 |
|
|
July 22, 2008 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
17 |
NCT00092222 |
Recruiting |
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity |
- Lymphoproliferative Disorder
- HHV-8
- Malignancy
- HIV
|
- Drug: Etoposide
- Drug: Interferon-alpha
- Drug: Rituximab
- (and 10 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Describe natural history
- Therapeutic efficacy and toxicity of several rationally designed therapeutic approaches to KSHV-MCD
|
55 |
All |
12 Years to 65 Years (Child, Adult) |
NCT00092222 |
040275 04-C-0275 |
|
September 20, 2004 |
October 1, 2018 |
October 1, 2020 |
September 22, 2004 |
October 19, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
18 |
NCT02863068 |
Recruiting |
Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers |
|
- Drug: Topical Sodium Nitrite
- Other: Placebo
|
Interventional |
Phase 2 |
- Montefiore Medical Center
- Food and Drug Administration (FDA)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Assessment of tolerability
- Ulcer size reduction
- Ulcer pain reduction
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02863068 |
2016-6015 R01FD005729-01 |
|
July 1, 2017 |
June 30, 2019 |
June 30, 2020 |
August 11, 2016 |
October 4, 2017 |
|
- Montefiore Medical center
The Bronx, New York, United States - University Of Pittsburgh
Pittsburgh, Pennsylvania, United States
|
19 |
NCT03179163 |
Recruiting |
Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans |
|
- Drug: Captopril Pill
- Drug: Enalapril Pill
- Drug: Hydrochlorothiazide
|
Interventional |
Phase 1 Phase 2 |
- Penn State University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- laser Doppler blood flow
- Systolic Blood Pressure
- Diastolic Blood Pressure
|
70 |
All |
40 Years to 65 Years (Adult) |
NCT03179163 |
STUDY3224 5R01HL093238 120058 |
H2SPharm |
July 20, 2016 |
August 31, 2020 |
August 31, 2020 |
June 7, 2017 |
June 7, 2017 |
|
- Pennsylvania State University
University Park, Pennsylvania, United States
|
20 |
NCT03465917 |
Recruiting |
Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation |
|
- Combination Product: Renal Denervation
|
Interventional |
Early Phase 1 |
- University of Texas Southwestern Medical Center
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Renal sympathetic activity
- Blood pressure
- Muscle sympathetic activity
- (and 2 more...)
|
5 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03465917 |
STU 112014-023 |
|
March 1, 2018 |
February 2019 |
February 2019 |
March 14, 2018 |
March 14, 2018 |
|
- The Institute for Exercise and Environmental Medicine
Dallas, Texas, United States
|
21 |
NCT02230891 |
Recruiting |
Biomarker Guided Therapies in Stage A/B Heart Failure |
- Hypertension
- Diabetes
- Cardiovascular Disease
|
- Drug: Carvedilol
- Drug: Spironolactone
|
Interventional |
Phase 2 |
- VA Office of Research and Development
- Baylor College of Medicine
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Cardiac Strain
- Change in biomarkers
- arterial stiffness
|
210 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02230891 |
CLNB-009-13F |
|
October 1, 2014 |
December 31, 2018 |
December 31, 2018 |
September 3, 2014 |
January 4, 2018 |
|
- Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States
|
22 |
NCT02816736 |
Recruiting |
EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) |
|
- Drug: LCZ696
- Drug: valsartan
- Drug: LCZ696 placebo
- Drug: valsartan placebo
|
Interventional |
Phase 4 |
- Duke University
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in NT-proBNP
- Composite endpoint of the effects of LCZ696 (number of days)
- Tolerability - target dose
- (and 6 more...)
|
400 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02816736 |
Pro00071722 5U01HL084904 |
HFN-LIFE |
March 2, 2017 |
September 30, 2019 |
March 30, 2020 |
June 29, 2016 |
April 24, 2018 |
|
- Cedars-Sinai Heart Institute
Beverly Hills, California, United States - Sutter Health Mills-Peninsula Health Services
Sacramento, California, United States - San Diego Cardiac Center
San Diego, California, United States - (and 36 more...)
|
23 |
NCT02014246 |
Recruiting |
Genetic Characterization of Movement Disorders and Dementias |
- Ataxia
- Dystonia
- Parkinson's Disease
- (and 12 more...)
|
|
Observational |
|
- National Institute on Aging (NIA)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Other
|
- Identify and characterize genetic contributions to etiology for movement disorders, such as dystonia, Parkinson's disease, and dementias, such as Alzheimer's disease, Lewy Body Dementia, frontotemporal dementia.
|
12000 |
All |
18 Years and older (Adult, Senior) |
NCT02014246 |
999903329 03-AG-N329 |
|
February 12, 2003 |
December 31, 2018 |
December 31, 2018 |
December 18, 2013 |
April 25, 2018 |
|
- National Institute of Aging, Clinical Research Unit
Baltimore, Maryland, United States
|
24 |
NCT02035761 |
Recruiting |
PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA) |
- Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
- Multiple System Atrophy - Cerebellar Subtype (MSA-C)
|
|
Observational |
|
- University of Michigan
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Cardiac denervation
- MSA Rate of Progression
|
26 |
All |
30 Years to 80 Years (Adult, Senior) |
NCT02035761 |
NS044233 |
|
July 2011 |
July 2018 |
July 2018 |
January 14, 2014 |
September 25, 2017 |
|
- University of Michigan - Department of Neurology
Ann Arbor, Michigan, United States
|
25 |
NCT03076671 |
Recruiting |
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease |
- Parkinson Disease
- Parkinsonism
- Lewy Body Disease
- (and 4 more...)
|
- Behavioral: Palliative Care
|
Interventional |
Not Applicable |
- University of Colorado, Denver
- National Institute of Nursing Research (NINR)
- University of California, San Francisco
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quality of Life Alzheimer's Disease (QOL-AD)
- Zarit Burden of Care Instrument (ZBI)
- McGill Quality of Life Questionnaire (MQOL)
- (and 11 more...)
|
632 |
All |
18 Years to 105 Years (Adult, Senior) |
NCT03076671 |
16-1400 R01NR016037-01A1 |
MTMD |
March 1, 2017 |
February 28, 2021 |
September 30, 2021 |
March 10, 2017 |
March 8, 2018 |
|
- University of California, San Francisco
San Francisco, California, United States - University of Colorado Denver
Aurora, Colorado, United States
|
26 |
NCT01960075 |
Recruiting |
Established Status Epilepticus Treatment Trial |
- Benzodiazepine Refractory Status Epilepticus
|
- Drug: Fosphenytoin
- Drug: Levetiracetam
- Drug: Valproic acid
|
Interventional |
Phase 3 |
- University of Virginia
- University of Michigan
- Medical University of South Carolina
- (and 3 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical cessation of status epilepticus
- Occurrence of life threatening hypotension or cardiac arrhythmia
- Admission to ICU
- (and 6 more...)
|
795 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01960075 |
18078 119756 U01NS088034 |
ESETT |
October 2015 |
December 2019 |
July 2020 |
October 10, 2013 |
January 5, 2018 |
|
- Banner University Medical Center - South Campus
Tucson, Arizona, United States - Banner University Medical Center-Tucson Campus
Tucson, Arizona, United States - Ronald Reagan UCLA Medical Center
Los Angeles, California, United States - (and 62 more...)
|